Savara Inc. (SVRA) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, Savara Inc. scores 35 out of 100, a letter grade of D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 7/20 (ROIC of -35%; FCF yield of -9.94%); Whale 13F Flow at 7/20 (institutional accumulation and options positioning); Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 8/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.15). The weakest pillar is Insider Conviction, and the Fundamental Cash Engine is also in the low range, reflecting negative return on invested capital and negative free cash flow yield. The Forensic Balance Sheet pillar is the strongest of the five, but it still sits at half of its maximum. For a prospective investor, the rating indicates that the reported cash-generation and insider-signal inputs do not currently offer support, and that the balance-sheet inputs are only moderately supportive. Upside drivers would need to come from catalysts outside the reported financial metrics; the source data does not quantify valuation tradeoffs beyond the market capitalization and price shown below.

Savara Inc. (SVRA) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, it has a market capitalization of $1.0B. The source data does not describe its products, customers, or revenue model. Reported revenue for FY 2025 and FY 2024 is $0.0M in the SEC financials, so the source data does not show a revenue-generating business in those periods.

Per the SEC financials, reported operating and net losses widened across the three periods, and free cash flow was negative in each. Gross, operating, and net margins are each listed as 0% in the market data. Per the Roarable RQD rating, ROIC is -35% and the Altman Z-Score is 2.5, with a Piotroski F-Score of 3/9 and Debt/Equity of 0.15. The source data does not provide a Piotroski F-Score breakdown or an explanation of how these metrics were calculated.

The news wire contains six items tied to SVRA. Headlines reference long-term molgramostim data at CHEST 2026, a Citizens rating reiteration on a "Molbreevi launch outlook," a molgramostim data preview, a JP Morgan price target of $12.00/Share (reported by Moomoo), a Simply Wall St note on the stock jumping, and CHEST data presented ahead of an FDA decision. Three items carry a YELLOW light, two are MARKET WIRE, and one is a GREEN CATALYST item. The source summaries are generic and do not contain the underlying data. Risk watch items include the pending FDA decision and dependence on molgramostim data, as referenced in the headlines. The Butterfly Supply-Chain Graph contains no proprietary signals.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. The source data therefore does not establish upstream or downstream dependencies, sector correlations, or second-order bottlenecks. The only sector information available is the Health Care classification and Biotechnology: Pharmaceutical Preparations industry label, plus the Beta of 1.0. A prospective investor should treat the regulatory and clinical timeline referenced in the news headlines as the primary second-order sensitivity, since the source data does not quantify its effect.

• What are SVRA's products, approved indications, and revenue model, given that reported revenue is $0.0M in each listed period?
• What is the status and timing of the FDA decision and the molgramostim data referenced in the news headlines?
• What are the TTM EPS, forward earnings, and valuation multiples, since P/E and EV/EBITDA are unavailable?
• How much cash runway remains against the negative free cash flow reported in FY 2025 ($-101.1M)?
• What is the composition of institutional and insider ownership, given that the holders data is unavailable?